David J. Chang, MD, Mph, Facr
About David J. Chang, MD, Mph, Facr
Chief Medical Officer at Cabaletta
David J. Chang joined Cabaletta in June 2019 and currently serves as the Chief Medical Officer. In this role, he spearheads the company's medical strategies and oversees clinical development programs. His extensive experience in both biologics and small molecules development plays a crucial part in advancing Cabaletta's innovative therapies.
Previous Leadership at AstraZeneca Pharmaceuticals
Before joining Cabaletta, David J. Chang held the position of Senior Vice President and Head for Inflammation, Autoimmunity & Neuroscience in Global Medicines Development at AstraZeneca Pharmaceuticals LP. During his tenure, he was responsible for overseeing late-stage clinical development projects, guiding the development of biologics and small molecules across various indications.
Positions at GlaxoSmithKline plc
David J. Chang also served in various leadership roles at GlaxoSmithKline plc, most notably as Vice President and Head of Immuno-Inflammation, Clinical Development. His work was pivotal in the clinical development and registration of systemic lupus erythematosus products, marking significant advancements in the treatment of this condition in the United States.
Academic Background in Medicine
David J. Chang has an extensive academic background, having been a faculty member in the Division of Rheumatology at the Perelman School of Medicine at the University of Pennsylvania from 1997 to 2022. He holds an M.D. from New York University School of Medicine and an M.P.H. from Emory University. His undergraduate degree is a B.S. from Yale University. Additionally, he completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center, followed by a fellowship in Rheumatology at the Hospital for Special Surgery—Cornell University Medical Center.
Professional Affiliations and Contributions
David J. Chang is a Fellow of the American College of Rheumatology. His professional contributions include leadership in the clinical development of two systemic lupus erythematosus products approved in the US; the first approvals in over 60 years. His professional journey reflects a significant impact in both the pharmaceutical industry and academic medicine.